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1. Introduction
In many countries Type 1 diabetes [T1D] is the most common life-threatening disease in chil‐
dren, and nobody can be cured. For long time the incidence has increased all over the world
[1]. The disease causes serious morbidity and increased mortality [2,3] in spite of an intensive
treatment with multiple daily injections of insulin, adapted to regular meals with suitable
content based on self-monitoring of blood glucose. Many patients do never succed to get good
metabolic control because of the complicated treatment and another problem preventing good
metabolic control is hypoglycaemia [4]. Modern insulin pumps and glucose sensors have made
it possible to improve insulin treatment [5]. The simplest approach to reduce severity of hy‐
poglycemia when treatment is intensified is to interrupt insulin delivery. There are insulin
pumps with an integrated continuous glucose monitoring, which automatically suspends in‐
sulin delivery for up to 2 hours when hypoglycemia is detected even when the hypoglycemia
alarm is not acknowledged by the patient [6,7]. Closed-loop insulin delivery [artificial pan‐
creas] is aiming to achieve near normal blood glucose without increasing the risk of hypogly‐
cemia [8]. Thus a disposable sensor measures interstitial glucose levels, which are fed into an
algorithm controlling delivery of a rapid-acting insulin analog into the subcutaneous tissue by
an insulin pump. So far research has focused on closed loop insulin delivery during night, and
this technique is improving [9]. However, also in the future there will be need for the patient
to learn how to handle also these devices, not least during infections, longer exercise, and
several other situations and changes of life.
2. Introduction
Even though patients with T1D need insulin, the primary goal of novel therapies is to preserve
residual insulin secretion, in best case to cure diabetes or at least to make the disease milder
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and facilitate treatment. Patients with residual insulin secretion usually get lower HbA1c, and
residual insulin secretion facilitates the treatment, decreases the risk for serious hypoglycaemia
and the risk of keto-acidosis [10]. Already very modest beta cell function, with peak stimulated
C-peptide above 0.2 nmol/L seems to reduce long-term complications [11]. Furthermore, C-
peptide per se has been proposed to decrease the risk of complications, especially neuropathy.
There is increasing evidence that C-peptide is not just a connecting peptide to keep the two
insulin chains in in a certain structure, but a hormone with several important effects [12]. The
relevance of saving beta cells and improving their function has become even more evident
when studies suggest that beta cells may regenerate [13, 14]. If this is the case an end of the
destructive process might lead to cure of T1D [15].
3. The immunological disease process
The generally accepted opinion is that the majority of the pancreatic beta cells are lost at the
diagnosis of Type 1 diabetes. The beta cells are supposed to be killed by an autoimmune process
precipitated and promoted by genetic and environmental factors. In recent years the dogma
saying that most beta cells are dead has been questioned, and regeneration of the beta cells
seems not only possible but quite plausible. Actually that was discussed as a possibility already
several decades ago( Fig 1). Thus, many beta cells may still be living in pancreas although they
do not respond normally to stimulus with insulin secretion. Auto-antibodies are usually found,
but regarded as markers of the process, rather than causing beta cell death. The auto-antibodies
react against the islet cells (Islet Cell Antibodies; ICA) [16] or against specific auto-antigens
such as Insulin Auto-antibodies against Insulin (IAA) [17], against Glutamic Acid Decarbox‐
ylase (GADA) [18], against Tyrosin Phosphatase ( IA-2A) [19] or against ZincTransport Anti‐
gen (ZnTA) [20]. These antigens are attacked by the own immune system. Dysregulation of
the immune system is thought to allow a self-destructive process. Mononuclear cells, mainly
T-cells, seem to play the most important role for the killing of the beta cells.
4. Immune interventions
Several immune interventions have been tried since the 1970ies we tried plasmapheresis in
Linköping, Sweden, with the aim to preserve residual beta cell function, but so far all different
approaches have shown insufficient efficacy and/or given unacceptable adverse effects [21-28].
Broad immunosuppressive or immunoblocking therapies with steroids, cytostatics, high doses
of immunoglubulins, anti-lymphocyte globulins have shown some but unfortunately limited
efficacy, and adverse events have lead to restrictions both in dose and time. Our studies using
photopheresis did show some efficacy, and although the treatment was very laborious it has
regained some interest. However, most encouraging is the use of monocloncal antibodies,
especially against CD-3 [29-31] but also against CD-20 [32]. Unfortunately treatment with
monoclonal antibodies in doses large enough to give efficacy also cause rather common and
occasionally serious adverse events.Therefore such therapies are rarely justified as preventive
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interventions in healthy children with increased risk of developing T1D except for children
with extremely high risk of developing T1D close in time.
Figure 1. At a Nordic symposium in connection with Annual meeting of Scandinavian Society for the Study of Diabe‐
tes, Linköping 1981, the author showed this slide. Type 1diabetes was proposed to develop after a long autoimmune
process destroying the beta cells. Events during pregnancy and the importance of breast-feeding was suggested, and
later shown to be relevant, and regeneration of beta cells was proposed as a possibility.
After encouraging Phase II trials two different Phase III trials using antiCD3 failed to reach
their primary endpoints [33,34], but one of them, the Protégé study, did show efficacy in
younger patients age 8-18 years when a reasonably high dose of antiCD-3 was used [34]. This
was especially true in certain patient populations (mainly patients in USA, but also in Europe)
who had rather well preserved C-peptide, often near-normal HbA1c and low insulin require‐
ment. Further studies are needed to learn what doses are efficient without severe adverse
events, and in what patient populations the treatment works best. The old policy defended by
many diabetologists to treat all so called T1D in the same way irrespective of age, ethnic back‐
ground, severity of disease at diagnosis etc may probably have to be left.
5. Vaccines against infections
Traditional vaccinations could either contribute to the development of T1D, or T1D could be
prevented by vaccination. Already in the 1920ies mumps infection was shown to be a possible
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cause of insulin dependet diabetes [35]. A general vaccination against mumps might then
either decrease the incidence of T1D, or vaccination with living virus might on the contrary
initiate an autoimmune process leading to an increased incidence of T1D. None of these asso‐
ciations have been proven [36, 37]. Neither have there been any associations between vacci‐
nations against other microbes and the development of diabetes [38]
Entero virus infections are most suspected to cause T1D. Epidemiological studies have pro‐
vided evidence of coxsackie virus (CVB) infections in subjects who later develop T1D [39]. A
CVBB4 strain E2 was isolated from pancreas of a diabetic child, and the virus was then passed
into islet cells and found to cause diabetes in mice, which was taken as a proof of the concept
that coxsackievirus can cause T1D [40]. So far vaccination against these types of infections to
preserve beta cells has been disappointing,
The hygiene hypothesis suggests that the immune system would deviate less often towards
an autoimmune process if the immune system was occupied by an ongoing defence against
serious enemies. In accordance with this hypothesis, Calmette vaccination has been tried to
preserve beta cell function but no clinical effect has been seen [41].
6. Immune intervention by probiotics
Several findings indicate that the gut is involved in the development of the disease process
leading to T1D [42]. The intestinal barrier may be disturbed. This might facilitate passage of
proteins which could contribute to the autoimmune process. Cows milk [43], and bovine in‐
sulin in cows milk has been suggested as a possible cause of an autoimmune reaction against
insulin [44]. Maturation of the immune system may also be influenced by the gut flora. Pro‐
biotics can probably influence immune function through effects on antigen-presenting cells,
regulatory T cells and effector T and B cells [45] and probiotics may prevent autoimmune
diabetes in NOD mice [46,47]. However, although use of probiotics would be attractive as the
adverse events can be expected to be minimal, there are so far no studies proving any effect
7. Heat shock protein used in immune intervention
Studies in experimental animals have shown that use of a 65-kDa heat shock protein can pre‐
vent diabetes [48]. A specific peptide, Diapep 277, seems to be the active component and this
peptide has been tried with interesting effects.
Clinical trials in humans have shown that sc administration of Diapep 277 may preserve beta
cell function in adults [49]. Thus 35 patients with type 1 diabetes and basal C-peptide above
0.1 nmol/L were assigned to subcutaneous injections of 1 mg Diapep277 and 40 mg mannitol
in vegetable oil The primary endpoint was glucagon-stimulated C-peptide production. At 10
months, mean C-peptide concentrations had fallen in the placebo group (n=16) but were main‐
tained in the DiaPep277 group (n=15; p=0.039). Need for exogenous insulin was higher in the
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placebo than in the DiaPep277 group. There were no o adverse events. The treatment of newly
diagnosed T1D adults with DiaPep277 seemed to preserve residual insulin secretion through
induction of a shift from Thr-1 to Thr-2 cytokines. However, the efficacy seen in adults could
not be confirmed in children and adolescents with T1D [50,51] in spite of interesting immu‐
nologcval results [52]. In a recent Phase III trial no immunological difference could be found
between adults treated with Diapep 277 or those treated with placebo [53]. Treatment with
Diapep 277 seemed to preserve C.peptide but only C-peptide after Glucagon stimulation, but
not after Mixed Meal Tolerance Test [54]. Thus it is still unclear whether Diapep 277 has a place
or not as future intervention to preserve residual insulin secretion in adults.
8. “Inverse vaccination “to reduce the immune response
Traditional vaccination is strengthening the immune reaction against an antigen, usually an
infectious microbe. Methods of reducing a pathological specific immune response eg in auto‐
immune diseases like T1D can be regarded as a sort of “inverse” vaccination. In allergy toler‐
ance against the allergens is created by presenting the antigen/allergen/s in gradually
increasing doses. Such Immunotherapy has become quite efficacious [55] and the adverse
events are rare.
It would be reasonable to try to reduce an autoimmune process in an analogue way, by ad‐
ministration of auto-antigen/s. Thus, instead of suppressing the immune system, the immune
response should be modulated by presenting antigen/s in a way that the immune system shifts
from a destructive process to tolerance [56].
If self-reactive T-cells directed against auto-antigens cause some cases of Type 1 diabetes a
major question is why such self-reactive T-cells occur. Two mechanisms seem to be necessary
for self-tolerance: Clonal deletion of self-reactive T-cells issued from the random recombina‐
tion of genes (negative selection), and generation of self-antigen-specific natural regulatory T-
cells (Tregs) which can inactivate self-reactive T-cells in the periphery when they have escaped
intra-thymic negative selection [57]. In T1D auto-reactivity against insulin is a common and
early phenomenon. The important role of thymic insulin for development of self-tolerance has
been demonstrated in transgenic mice [58], but there is still no technique to use this knowledge
in clinical practice.
9. Auto-antigen treatment
9.1. “Vaccination” with insulin
Proinsulin and insulin and its different chains are so far the only known auto-antigens that are
specific for the beta cells. Insulin has been used in trials to prevent diabetes among first degree
relatives with increased risk of T1D. In Diabetes Prevention Trial-Type 1 Diabetes (DPT-1)
human ultralente insulin of 0.25 units x kg/day, or placebo, was given to subjects with >50%
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5-year risk of getting T1D. To give such large doses of insulin sc every day can not be regarded
as immune intervention, but rather as beta cell support. In any case this type of treatment failed
to reach the end-point [59].
Oral insulin is not supposed to be absorbed enough to affect blood glucose or to support re‐
maining beta cells, but such an administration can be regarded as immune intervention. The
DPT-1 trial randomized 372 relatives of subjects with T1D, positive for IAA and with normal
intravenous and oral glucose tolerance test (IVGTTs and OGTTs), to oral insulin 7.5 mg daily
or placebo. Although the result was negative when comparing the groups with the pre-speci‐
fied inclusion criteria, subanalyses suggested that Type 1 diabetes was significantly delayed
in those individuals who had higher concentrations of IAA [60]. This suggests that auto-anti‐
gen therapy may be most efficaceous in patients whose immune system reacts strongly against
a certain antigen.
The first diabetes-related auto-antibodies in young children are usually IAA and therefore
insulin has been tried to prevent diabetes in high risk individuals. Intranasal proinsulin had
effect in experimental animals [61] but intranasal administration of insulin in high risk children
had no effect [62]. Administration of the insulin B-chain can prevent diabetes in experimental
animals [63]. A combination of the insulin B-chain fragment with Freunds adjuvant has been
tried also in newly-diagnosed T1D adults [64]. There was effect on T-regulatory cells but no
significant effect on C-peptide.
9.2. GAD-vaccination
During our studies with plasmapheresis [21] we discovered a new diabetes-related antigen,
64kD [65], which later on was found to be glutamic acid decarboxylase (GAD [66]. Auto-an‐
tibodies towards GAD are common in T1D and there are convincing results from studies of
experimental animals that treatment with GAD can prevent autoimmune diabetes [67, 68]..
An adjuvanted formulation, based on Alhydrogel®, a product of Aluminum hydroxide
(alum),was developed to provide a drug (Diamyd®) used for evaluation in clinical trials. Al‐
hydrogel® is used as adjuvant in vaccines for children eg DTP, Pneumococcal conjugate, Hep‐
atitis B, Hepatitis A vaccines. Aluminum salts are inducing a humoral (Th2) rather than cellular
immune response. As the T1D autoimmune process is deviated towards Th1 (or cellular) re‐
sponse to autoantigens, alum is used to counteract this deviation and “steer” the response
induced by GAD away towards a Th2 response. Inclusion of adjuvant is also a way to minimize
the quantity of antigen required for treatment.
Diamyd® preclinical safety studies were done and caused no concerns for clinical safety.
Evaluation of the effects of Diamyd® in several different animal models of autoimmune dis‐
ease did not indicate any undesirable effects on the immune system. Phase 1 studies in humans
were performed 1999.A randomized, double-blind and placebo-controlled dose-finding Phase
IIa study in 47 LADA demonstrated efficacy in beta cell preservation in the 20-µg group [60]
There were no Serious Adverse Events (SAEs) ) and even though the number of patients was
very small, this result was encouraging. Follow-up after five years completed 2008 still showed
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a significantly beneficial effect of the 20µg dose of Diamyd®, and there had been very few AE,
none of them considered to be treatment related [70]
A Phase IIb, randomized, double-blind, placebo-controlled multicenter Diamyd® study in 160
LADA-subjects was then performed in Sweden. Subjects received 20 µg of GAD65 or placebo
on 2 occasions 4 weeks apart. The trial had a main study period of 18 months and was scheduled
for unblinding in June 2007. Unfortunately, the study had to be invalidated due to concerns
regarding the labeling process of the investigational product. No safety concerns were raised
and no SAEs had been observed during 30 months observation.
9.3. GAD vaccination in children and adolescents
To investigate safety and efficacy of Diamyd® in T1D, a Phase II clinical trial in 70 recently
diagnosed T1D children and adolescents was performed [71]. The study was a randomized,
double-blind, placebo-controlled multicenter study using the same dose regimen as in the
successful group of the previous LADA trial. The main study period of 15 months was com‐
pleted and the trial partly unblinded for sponsor and statistician but continued blinded for all
other investigators for another 15 month follow-up. Outcomes from this study provided sup‐
port for clinical safety and efficacy after administration of Diamyd®. The treatment was very
well tolerated and there were no treatment-related adverse events reported still after more
than 4 years follow-up. Both treatment groups showed a gradual decline from baseline of both
fasting and stimulated C-peptide secretion. There was no significant effect of treatment on
change in fasting C-peptide after 15 months (primary endpoint). However, there was a sig‐
nificant efficacy seen on change in fasting C-peptide after 30 months (p=0.045), which remained
signficant when change in C-peptide/plasma glucose ratio was taken into account (p=0.02).
Furthermore, stimulated C-peptide secretion, as measured by area under the curve (AUC),
decreased significantly less in the GAD-alum treated group compared to the placebo group,
both after 15 months (p=0.01) and after 30 months (p=0.04). The significant effect of treatment
as change in fasting and stimulated C-peptide at month 30 remained when adjusting for du‐
ration of diabetes, age, gender, and baseline GADA levels.
However, although the c-peptide preservation was evident the insulin requirement in both
treatment groups increased in the course of the study, and HbA1c, and plasma glucose levels
increased during the study. HbA1c did not differ between the groups.
Duration of diabetes was very important for the efficacy of treatment (p=0.05 for fasting at
month 30 and p=0.03 for stimulated C-peptide area under the curve at month 15 and 30). In
patients treated within 6 months of diagnosis both fasting and stimulated C-peptide secretion
(AUC), decreased significantly less in the GAD-alum treated group as compared to the placebo
group over 30 months (fasting, p=0.03, and stimulated p=0.04) while no such difference was
seen in patients with a longer duration of diabetes ( Fig 2). The treatment effect in the short
duration was still seen after more than 4 years follow-up [72] in patients with < 6 months
duration of diabetes at treatment. There were no treatment-related adverse events.
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Mean changes from baseline in fasting (panelA) and stimulating (Panel B) c-peptide are fiven for all patients included
in intention to treat analyses in the group receiving the recombinant human 65-kD isoform of glutamic acid decarbox‐
ulase in a standard vaccine formulation with alum (GAD-alum. 35 patients) and in the group receiving placebo (34
patients). Mean changes from baseline in fasting (Panel C) and stimulated (Panel E) C-peptide levels are also shown for
those patienst treated less then 6 month after receiving the diagnosis of diabetes (11 patients in GAD-alum group and
14 patients in the placebo group). Finally, mean changes from baseline in fasting (Panel D) and stimulated (Panel F) C-
peptide levels are shown for those treated 6 months or more after diagnosis (24 patients in the GAD-alum group and
20 patients in the placebo group). Stimulated C-peptide level was measured on the basis of areas under the curve in
response to the mixed-meal tolerance test. I bars indicate standard errors. To convert values for C-peptide to nano‐
grams per milimeter, devided by 0.33.
Figure 2. Mean Changes from Baseline Levels of Fasting and Stimulating C-Peptide, According to Treatment Group
and Time of Treatment Relative to Diagnosis.
The Phase II trial was followed by aPhase III trial in Europe. 334 patients age 10- 20 years were
included, with diabetes duration < 3 months at screening, fasting C-peptide >0.1 nmol/l and
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pos GADA. In this study the two arms of the Phase II study ( placebo resp 20 µg of GAD65
(Diamyd® ) with 30 days interval, were the same, but in addition there was a third arm where
the patients got 20 µg of GAD65 (Diamyd® ) sc also at Day 90 and 270 when the patients in
the other arms got placebo injections. The primary endpoint was difference in C-peptide AUC
after a Mixed Meal Tolerance Test. Surprisingly the study failed! [73]. The difference in AUC
was only 16-18 % between the actively treated patients and the placebo group ( p= 0.10) and
the difference in fasting C-peptide was similar ( p= 0.07). However, in several prespecified
subgroups the efficacy was quite pronounced (around 30-40%), and significant.. When com‐
bining Phase II and that arm in Phase III in which the patients received 2 doses of GAD-alum,
then theefficacy measured both as fasting C-peptide and AUC after MMTT seems quite im‐
pressive after 30 months.
The question arises why the results in Phase III was so much weaker than in Phase II. There
are some possible explanations: In Phase III the patients who received active drug by chance
were more often 10-11 years old whereas patients in the placebo group more frequently were
16-20 years old than in the actively treated arms. It is well known that younger patients loose
their residual insulin secretion more rapidly and therefore this difference in ages might have
influenced the result. There are also other facts which may have played a role. Thus, in the
Phase II trial the patients were treated in March –April and when looking at patients in Phase
III who were treated in March-April there was in fact also significant effect of GAD-treatment.
Finally, in the Phase II trial no vaccinations were accepted, but in Phase III Influenza-vaccina‐
tion was allowed. Unfortunately an epidemic of H1N1-flu lead to that almost all patients were
vaccinated, many of them in connection with the GAD-vaccinations. In Sweden and Finland
the vaccine contained squalen, suspected to influence the immune system towards auto-im‐
munity, and in these two countries there was no efficacy of GAD-treatment, while there was
efficacy in other European countries. Patients in Sweden, who did not get the influenza vac‐
cination close to the GAD-treatment, had better effect of the GAD-treatment [73].
9.4. GAD-vaccination and the immune system
In both the Phase IIb and the European Phase III patients treated with two doses of GAD-alum
got increasing GADA levels with a a maximum after 3 months and then a gradual decrease
even if the concentrations of GADA remained significantly higher than in the placebo group.
Four doses given in the Phase III trial lead to even higher GADA levels. Increase of GADA had
neither relationship to efficacy of the vaccination, nor to adverse events. There was no change
of epitopes related to development of Stiff Person Syndrome, but a rather small but significant
shift in isotypes with reduced percentage of IgG1 and increased IgG3/IgG4 detected in GAD-
alum treated patients[74], in agreement with a Th2 deviation. Spontaneous/non-stimulated
and PHA-induced secretion of all cytokines was similar in samples from children receiving
GAD-alum and placebo, both before and 15 months after the first injection. Cytokine secretion
of IL-5, IL-10, IL-13, IL-17, IFN-γ and TNF-α, but not of IL-6 and IL-12, in response to in vitro
stimulation with GAD65 increased in GAD-alum treated patients from baseline to month 15,
but a continuous increase was only seen in IL-5, IL-10 and IL-13 while other cytokines remained
elevated but at a stable concentration [75]. This indicates that the treatment caused a Th2-
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deviation. The immunological effects were long lasting immune responses, as they remained
still 48 months after the first injection [75].
As a sign of increase of T-regulatory cells we noticed an increased GAD65-induced expression
of FOXP3 and TGF-β at month 15 in cells from GAD-alum treated patients compared to pla‐
cebo, and the expression of FOXP3 and TGF-β correlated positively in the GAD-alum group
but not in the placebo group[77]. Still after 48 months there were clear effects on the immune
system suggesting both a Th2 deviation, a decrease of activated T-cells (CD4+CD25+high) but
increase of FoxP3-positive regulatory T-cells. Thus, our interpretation is that Diamyd® treat‐
ment deviated the immune system towards tolerance against the auto-antigen GAD.
9.5. Other trials with GAD vaccination
Beside the European phase III trial discussed above [73], a similar trial was started a bit later
in USA (US Phase III ClinicalTrials.gov Identifier: NCT00751842 ;Jerry Palmer, PI), with the
same design. The recruitment was not so fast as initially only patients >16 years old were
accepted, and therefore the recruitment had just finished when the negative results of the
European Phase III trial was found. This lead to that the American trial was stopped, before it
can give any results. In addition another intervention trial in newly-diagnosed Type 1 diabetic
patients aged 3-45 years was performed by TrialNet (TrialNet Intervention ClinicalTrials.gov
Identifier: NCT00529399). Patients were randomized in a double-blind controlled study into
three arms, one with subcutaneous injections of 20 µg GAD65-alum (Diamyd®) at day 1,30
and 90, a second arm with subcutaneous injections of 20 µg GAD65-alum (Diamyd®) at day
1,30 and placebo at day 90, and a third arm with placebo at all time points The study failed.
No effect on C-peptide preservation was found [77]. So far little has been presented from this
trial with regard to effects on the immune system. It is difficult to know what the wide age
range, variation in ethnic groups, BMI etc meant for the result.
9.6. Ongoing or planned GAD-alum studies
Because of the positive results in the Swedish Phase II study and the positive results in some
prespecified subgroups in the European Phase III trial, new studies are planned. As the Phase
III trial failed, GAD-alum will be given as part of combination therapy, which hopefully will
give a better effect on the disease process. Thus a new pilot trial is just on its way when GAD-
alum is combined with Vitamin D, which is supposed to positively influence the dendritic
cells, contribute to Th2 deviation, but also influence directly beta cell survival and insulin
sensitivity. In addition a third drug, anti-inflammatory, will be given to dampen the inflam‐
mation, which might play an important and negative role beside the autoimmune process.
In addition to interventional trials at onset of Type 1 diabetes a pilot trial with the aim to prevent
T1D is ongoing in southern Sweden. High risk children have been identified as part of the so
called DiPiS (Diabetes Prevention in Skåne) study, in which newborn children in the general
population have been screened for auto-antibodies. Children positive for GADA, plus at least
one more diabetes-related autoantibody, have been treated with either 20 µg GAD65-alum
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(Diamyd®) or placebo subcutaneous at day 1 and 30. As the study is not powered for efficacy
the main aim is to study safety.
10. DNA vaccines
T-cells respond to antigens presented by antigen presenting cells (APCs).DNA-vaccines can
be used to present the antigen instead of delivering intact proteins. A protein encoded by a
plasmid DNA can either be produced outside the APCs if the pasmidDNA is administered
into a muscle, or the plasmidDNA may be taken up by the APCs where the encoded protein
is presented [78]. Proteins encoded by DNA vaccines can induce different types of antigen-
specific immune responses, and perhaps also some non-specific reactions.
Most common routes of administration are either intramuscular, which is thought to favour
Th1 responses, or intradermal, which is thought to favour Th2 response. For treatment of Type
1 diabetes intradermal injection should be most interesting. Another way of skewing the re‐
sponse towards Th2 may be to co-administer plasmids encoding Th2 cytokines.
Promoters from virus, eg Cytomegalovirus, can be used. Certain sequences seem to stimulate
Th1 response and should therefore be avoided in treatment of T1D.
So far DNA-vaccines to create tolerance in autoimmune disease have been tried mainly in
experimental animals. Plasmid DNA encoding for proinsulin [79] as well as for the insulin B
chain [80] have been used for prevention of diabetes in experimental animals. Injection of
plasmidDNA encoding for GAD has been shown effective in preventing diabetes in NOD-
mice [81], while similar effect have been seen by combining plasmidDNA encoding for a fusion
protein consisting of both GAD, IgG and IL4 [82]. Treatment with a recombinant vaccinia virus
expressing GAD ( rVV-GAD65) has also shown to be effective in prevention of autoimmune
diabetes in NOD mice by induction of active suppression of effector T-cells [83]. IgG1 anti‐
bodies and IL-4 increased and the IgG2 was unchanged, suggesting a Th2 deviation.Before
clinical use there are several problems which need to be solved. Correct dosing is necessary as
wrong dose might give increased immune response and a more aggressive disease process In
addition it is important to be sure that the DNA is not integrated in the host chromosome.
Another problem might be production of antibodies against DNA.
11. Beta cell regeneration
The traditional generally accepted view is that when a patient gets Type 1 diabetes there is no
longer any capacity of the beta cells to regenerate. However, there are almost no studies on
beta cell regeneration in humans. In recent years some studies suggest that the old paradigm
may be wrong and that beta cells in fact can regenerate. GLP-1 might stimulate beta cell re‐
generation.and GLP-1 agonist (Exenatide) in combination with monoclonal antibodies inter‐
fering with IL-2 ( Daclizumab) was given to patients with longstanding Type 1 diabetes with
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some residual insulin secretion, to see whether the treatment could increase C-peptide, but in
this study the result was negative [84].
Administration of INGAP (islet neogeneis associated protein)in anaimals has caused increased
beta cell mass and reversal of hyperglycemia, and hopefully INGAP has regenerating capacity
in humans. Daily introductionf of INGAP or placebo has been tried in a double-blind random‐
ized trial in both Type 1 and Type 2 diabetic patients [85], and it showed increased arginin-
stimulated C-peptide during the treatment period, but the effect was very short. Already after
30 days the effect was lost, which does not indicate any influence on beta cell mass as such an
effect should have been much longer
12. Vitamin D and type 1 diabetes
Experimental studies suggest that vitamin D may play a role in the defence against type 1
diabetes as well as type 2 diabetes. Epidemiological data suggest that there is a link between
vitamin D deficiency and an increased incidence of Type 1 diabetes. A multinational case-
control study and a birth cohort follow-up study from Finland [86] have concluded that vita‐
min D3 supplementation at birth protects against type 1 diabetes later in life, and a meta-
analysis supports similar conclusions [87]. Low serum levels of 1α,25-dihydroxyvitamin D3
[1,25(OH)2D3, calcitriol] has been found in patients with recently diagnosed type 1 diabetes.
The protective effects of vitamin D against diabetes are mediated through the regulation of
several components such as the immune system and calcium homeostasis. Thus, mechanistic
studies show that 1,25(OH)2D3 modulates dendritic cell maturationand facilitates a shift from
a Th1 to a Th2 immune response. There is also ncreasingevidence suggesting that vitamin D
also affects beta cells directly thereby rendering them more resistant to cellular stress. There
are results indicating that Vitamin D may also improve insulin sensitivity, which in turn de‐
crease beta cell stress.
Vitamin D has been used in patients with recent onset Type 1 diabetes in an effort to preserve
residual insulin secretion. However, so far Vitamin D alone has not been efficacious [88. 89]. It
seems resaonable to try Vitamin D, both in higher dose, and in combination with other therapy.
13. Anti-inflammatory treatment
In diabetes, both Type 1 and Type 2, there are signs of inflammation, partly related to gluco‐
tixicity, partly to other traits of the disease. Thus also in Type 1 diabetes there is an inflamma‐
tory componenent in addition to the autoimmune process. IL-1 has been proposed to be of
special importance for the destruction of pancreatic beta cells [90], and blocking IL-1 in ex‐
perimental animals has shown important effects on the disease process. Use of IL-1 inhibitor
in Type 1 diabetes has shown reduced serum interleukin 8 (IL-8) levels and reduced CD11b
integrin expression on monocytes associated with increased CXCR1 expression. These effects
suggest that blocking the IL-1beta pathway results in a reduced ability of mononuclear cells
Type 1 Diabetes504
to go to sites of inflammation. However, there is a great gap between studies in animals and
and in vitro mechanistic studies, to clinical studies in humans. Recently at the Congress of
American Diabetes Association and at the Immunology Diabetes Society the results of two
trials blocking the effect of IL-1 in Type 1 diabetes failed. Thus, the use of IL-1r-antagonist
showed no effect on preservation of C-peptide or any related clinical parameter[91], and the
same was unfortunately the case in another Phase II trial using a IL-1 antagonist, Anakinra [92].
Furthermore blocking IL-1 caused adverse events. Thus, as single therapy using anti-inflam‐
matory drugs is not good enough, but should be tested in combination with other therapies.
14. Future perspectives of immune intervention
No single therapy has shown to be an effective immune intervention in manifest Type 1 dia‐
betes for preservation of residual insulin secretion. As well as successful treatment of child‐
hood leukemia and cancers needed combination of several drugs, it will most probably be
necessary to use combination therapies also for Type 1 diabetes. Auto-antigen treatment will
probably be part of such future clinical treatment and/or prevention of Type 1 diabetes. Even
though GAD-alum so far has not shown any stable efficacy, and Diapep 277 has shown slight
efficacy only in adults with good C-peptide preservation, future studies will tell us how to use
auto-antigen therapy more effectively, and then in combination with other therapiesIt may be
so that treatment with GAD may be useful in patients with immune recognition of GAD, and
treatment with proinsulin or insulin/insulin chains may be useful in patients whose immune
system recognizes these auto-antigens. Furthermore, the effect might be improved by combi‐
nation therapies with eg Vitamin D, anti-inflammatory drugs, perhaps also in combinations
with monoclonal antibodies. New ways of administration may be important and/or DNA-
vaccines may be found to be another effective way of creating tolerance against auto-antigens,.
In spite of recent failures of some immune interventions in clinical trials knowledge is growing
and there may soon be a breakthrough.
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